TABLE 9.
Active immunity against mutans streptococci in humans
| No. of subjects in study group | Immunization route | Antigens (serotype) | Vehicle or adjuvant | Increase in:
|
Decrease in the level of S. mutans | Reference | |
|---|---|---|---|---|---|---|---|
| Salivary IgA antibodies against S. mutans | Serum antibodies against S. mutans | ||||||
| 3 | Topical (lower lips) | Whole cells (c) | Capsule | No | NTa | Yesb | 247 |
| 11 | Oral | Whole cells (d) | None | No | NT | Yesb | 152 |
| 4 | Oral | Whole cells (d) | None | No | No | Yesb | 40 |
| 8 | Oral | Whole cells (d) | Capsule | No | No | Yesb | 89 |
| 5 | Oral | Whole cells (indigenous) | Capsule | Yes | No | Yes | 170 |
| 25 | Oral | Glucosyltransferase (g) | Aluminum phosphate, capsule | Yes | No | Yes | 442 |
| 23 | Topical (lower lips) | Glucosyltransferase (g) | Aluminum phosphate | Yes | No | Yes | 443 |
| 4 | Oral | Whole cells (d) | Capsule | Yes | No | NT | 325 |
| 5 | Oral | Whole cells (c) (indigenous) | Capsule | Yes | No | NT | 101 |
| 7 | Oral | Glucosyltransferase (c) | Liposome | Yes | NT | NT | 82 |
a
NT, not tested.
b
Decrease in implanted S. mutans.